Erythropoietin Market in Japan 2015-2019

  • Published: Sep 2015
  • Pages: 65
  • SKU: IRTNTR7268
Technavio

The 2021-2025 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

About erythropoietin
Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an excess of erythropoietin to maintain a normal level of red blood cells. When the endogenous production of erythropoietin is disrupted because of illness or medications, normal red blood cell levels are maintained by an injecting erythropoiesis-stimulating agents (ESAs). These agents are similar to natural erythropoietin in structure and function. They can be produced by recombinant DNA technology and are used in the treatment of anemia resulting from renal disease, cancer, HIV, injuries, or neurological conditions.

Technavio's analysts forecast the erythropoietin market in Japan to decline at a CAGR of (1.16) % over the period 2014-2019.

Covered in this report
In this report, Technavio covers the present scenario and growth prospects of the erythropoietin market in Japan for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of erythropoietin drugs and biosimilars used in the treatment of anemia due to renal disease, chemotherapy, antiretroviral therapy, wounds, or neurological conditions.

Technavio's report, Erythropoietin Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the erythropoietin market in Japan and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key vendors
• Chugai Pharmaceutical
• JCR Pharmaceuticals
• Kissei Pharmaceutical
• Kyowa Hakko Kirin

Other prominent vendors
• Eisai
• Otsuka
• Taiho Pharmaceutical
• Takeda

Market driver
• Increased incidence of anemia due to illness
• For a full, detailed list, view our report

Market challenge
• High cost of therapy
• For a full, detailed list, view our report

Market trend
• Strategic alliances 
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Read More Read Less

Part 01: Executive summary
Highlights 
Part 02: Scope of  the report
Market overview 
Top-vendor offerings 
Part 03: Market research methodology
Research methodology 
Economic indicators 
Part 04: introduction
Key market highlights 
Part 05: Biosimilars/biologics industry
Overview 
Emerging role of biosimilars 
Factors influencing biosimilars / biologics market 
Biosimilars: business and pricing strategy 
Biosimilars industry point of view (providers, payers, buyers, vendors, regulatory bodies) 
Part 06: japan- country snapshot
Socio-economic factors 
Pharmaceutical industry in japan 
Biologics / biosimilars market in japan 
Regulatory landscape 
Healthcare reform 
Epo – addressable market in japan (epidemiology – oncology, ckd, hiv/aids, wound healing neurology) 
Part 07: Global erythropoietin market
Part 08: Market landscape
Market overview 
Market size and forecast 
Five forces analysis 
Part 09: Market segmentation by application
End stage renal disease 
Cancer 
HIV 
Wounds and neural disease 
Part 10: Market segmentation by product type
First generation erythropoietin formulation 
Second generation erythropoietin formulation 
Biosimilars 
Part 11: Market segmentation by end user
Hospitals 
Retail outlets 
Part 12: Market drivers
Part 13: Impact of drivers
Part 14: Market challenges
Part 15: Impact of drivers and challenges
Part 16: Market trends
Part 17: Vendor landscape
Competitive scenario 
Market share analysis 2014 
Other prominent vendors 
Part 18: Key vendor analysis
Chugai pharmaceuticals 
Jcr pharmaceuticals 
Kissei pharmaceutical 
Kyowa hakko kirin 
Part 19: Appendix
List of abbreviation

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>